High ROR1 expression in EGFR T790M NSCLC patients was related to an inferior progression-free survival in erlotinib-treated patients compared to those with low ROR1 expression, substantiating a role of ROR1 in the disease pathobiology and supporting that the inhibition of ROR1 might add to the therapeutic effect [79]. The gene discussed is ROR1; the disease is non-small cell lung carcinoma.